cerca CERCA
Lunedì 17 Gennaio 2022
Aggiornato: 16:55
Temi caldi

incorporated company

comunicato stampa

Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine

GAITHERSBURG, Md. and PUNE, India, Dec. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the World Health Organization (WHO) has granted Emergency Use Listing (EUL) for NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine wit...

comunicato stampa

Argon Medical Devices, Inc. Acquires Matrex Mold and Tool, Inc.

FRISCO, Texas, Dec. 14, 2021 /PRNewswire/ -- Argon Medical Devices, Inc., a leading manufacturer of medical devices for interventional procedures, announced the acquisition of Wisconsin-based Matrex Mold and Tool, Inc., a custom mold manufacturer for plastic injection molding. Matrex produces metal injection production and prototype molds for the medical device, residential, and automotive industries, and has done so since 1985. Argon was a customer of Matrex for over 25 years prior to the acquis...

comunicato stampa

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines

GAITHERSBURG, Md. and PUNE, India, Nov. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the Philippine Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vacc...

comunicato stampa

Novavax to Participate in World Vaccine Congress Europe

GAITHERSBURG, Md., Oct. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Vivek Shinde, M.D., Vice President, Clinical Development, will deliver a presentation during the World Vaccine Congress Europe 2021. A topic of discussion will be Novavax' COVID-NanoFlu™ Combination Vaccine, which combines the company's recombinant nanoparticle protein-based...

comunicato stampa

GC Aesthetics® Achieves Compelling Surgical And Patient Care Results With FixNip NRI™, The Revolutionary Nipple Reconstruction Device

DUBLIN, Oct. 5, 2021 /PRNewswire/ -- GC Aesthetics®, Inc. (GCA), a privately-held medical technology company providing aesthetic solutions for global healthcare markets, announces successful surgical and patient care results in its multi-centric safety and efficacy study for nipple reconstruction using the novel silicone implant, FixNip NRI™.

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

GAITHERSBURG, Md., June 14, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. The study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a repres...

EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines

PROVIDENCE, R.I., May 17, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the publication "Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation" in NPJ Vaccines. This research identifies peptide epitopes associated with T cell immunity to SARS-CoV-2 and confirms that recovering patients produce a memory immune response to iVAX-predicted epitopes. T cell immunity is an important component to long-term immune protection an...

EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology

PROVIDENCE, R.I., April 27, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the publication "Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs" in Frontiersin Immunology. This research highlights Tregitopes as a promising therapy for allergy. Administration of IgG-derived Tregitopes were found to induce suppressive antigen-specific T-regulatory cells in ovalbumin (OVA) and ragweed-allergic murine mouse models, attenuating allergen-induced airway hyperresp...

Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar

TAIPEI, March 24, 2021 /PRNewswire/ -- In a press conference today, EirGenix, Inc. (6589.TT) announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary endpoint. EG12014 has shown equivalent efficacy to Herceptin® in regards to its clinical response (pathologic complete response, pCR), in addition to demonstrating a comparable safety profile.  EirGenix will proceed...

International Consortium Led by Authentix, Inc. Finalizes License Agreement to Implement Major Track and Trace System in Pakistan

ADDISON, Texas and GAUTENG, South Africa and ISLAMABAD, Pakistan, March 10, 2021 /PRNewswire/ -- The Consortium of Authentix, Inc., MITAS Corporation and AJCL Private Limited is pleased to announce it has finalized a license agreement with Federal Board of Revenue of Pakistan to implement a track and trace system for tobacco, cement, sugar and fertilizer. The license agreement covers an initial five (5) year term as well as a three (3) year extension option.

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021"

JUPITER, Fla., Jan. 7, 2021 /PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today its Chief Executive Officer, President and Member of its Board of Directors Dr. Neil J. Campbell will participate in Biotech Showcase Digital and BIO @ JPM being held January 11-15, 2021.

FDA Awards $1.1M Contract to CUBRC and EpiVax for Validation of New Immunoinformatic Tool for Prospective Immunogenicity Assessment of Peptide Drugs and Their Impurities

PROVIDENCE, Rhode Island, Oct. 22, 2020 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announced today that they have been awarded a two-year, $1.1 million contract from the Office of Generic Drugs (OGD) in the Center of Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA) in response to a Broad Agency Announcement (BAA), FDA BAA-20-00123.

ora in
Prima pagina
articoli
in Evidenza